These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 21044092

  • 1. Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis.
    Siddappa NB, Hemashettar G, Wong YL, Lakhashe S, Rasmussen RA, Watkins JD, Novembre FJ, Villinger F, Else JG, Montefiori DC, Ruprecht RM.
    J Med Primatol; 2011 Apr; 40(2):120-8. PubMed ID: 21044092
    [Abstract] [Full Text] [Related]

  • 2. R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models.
    Siddappa NB, Watkins JD, Wassermann KJ, Song R, Wang W, Kramer VG, Lakhashe S, Santosuosso M, Poznansky MC, Novembre FJ, Villinger F, Else JG, Montefiori DC, Rasmussen RA, Ruprecht RM.
    PLoS One; 2010 Jul 21; 5(7):e11689. PubMed ID: 20657739
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K, Cecilia D, Ami Y, Nakasone T, Matsuo K, Burda S, Yamamoto H, Yoshino N, Kaizu M, Ando S, Okuda K, Zolla-Pazner S, Yamazaki S, Yamamoto N, Honda M.
    J Virol; 2005 Feb 21; 79(3):1452-62. PubMed ID: 15650171
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies.
    Gautam R, Nishimura Y, Lee WR, Donau O, Buckler-White A, Shingai M, Sadjadpour R, Schmidt SD, LaBranche CC, Keele BF, Montefiori D, Mascola JR, Martin MA.
    J Virol; 2012 Aug 21; 86(16):8516-26. PubMed ID: 22647691
    [Abstract] [Full Text] [Related]

  • 7. Molecularly cloned SHIV-1157ipd3N4: a highly replication- competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env.
    Song RJ, Chenine AL, Rasmussen RA, Ruprecht CR, Mirshahidi S, Grisson RD, Xu W, Whitney JB, Goins LM, Ong H, Li PL, Shai-Kobiler E, Wang T, McCann CM, Zhang H, Wood C, Kankasa C, Secor WE, McClure HM, Strobert E, Else JG, Ruprecht RM.
    J Virol; 2006 Sep 21; 80(17):8729-38. PubMed ID: 16912320
    [Abstract] [Full Text] [Related]

  • 8. Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection.
    Siddappa NB, Song R, Kramer VG, Chenine AL, Velu V, Ong H, Rasmussen RA, Grisson RD, Wood C, Zhang H, Kankasa C, Amara RR, Else JG, Novembre FJ, Montefiori DC, Ruprecht RM.
    J Virol; 2009 Feb 21; 83(3):1422-32. PubMed ID: 19019970
    [Abstract] [Full Text] [Related]

  • 9. Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers.
    Pauthner MG, Nkolola JP, Havenar-Daughton C, Murrell B, Reiss SM, Bastidas R, Prévost J, Nedellec R, von Bredow B, Abbink P, Cottrell CA, Kulp DW, Tokatlian T, Nogal B, Bianchi M, Li H, Lee JH, Butera ST, Evans DT, Hangartner L, Finzi A, Wilson IA, Wyatt RT, Irvine DJ, Schief WR, Ward AB, Sanders RW, Crotty S, Shaw GM, Barouch DH, Burton DR.
    Immunity; 2019 Jan 15; 50(1):241-252.e6. PubMed ID: 30552025
    [Abstract] [Full Text] [Related]

  • 10. Molecularly cloned SHIV-CN97001: a replication-competent, R5 simian/human immunodeficiency virus containing env of a primary Chinese HIV-1 clade C isolate.
    Liu Q, Li Y, Yang G, Dai J, Ruprecht RM, Shao Y.
    J Med Primatol; 2011 Dec 15; 40(6):427-36. PubMed ID: 21895680
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates.
    Saunders KO, Santra S, Parks R, Yates NL, Sutherland LL, Scearce RM, Balachandran H, Bradley T, Goodman D, Eaton A, Stanfield-Oakley SA, Tartaglia J, Phogat S, Pantaleo G, Esteban M, Gomez CE, Perdiguero B, Jacobs B, Kibler K, Korber B, Montefiori DC, Ferrari G, Vandergrift N, Liao HX, Tomaras GD, Haynes BF.
    J Virol; 2018 Apr 15; 92(8):. PubMed ID: 29437967
    [Abstract] [Full Text] [Related]

  • 14. Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges.
    Lakhashe SK, Velu V, Sciaranghella G, Siddappa NB, Dipasquale JM, Hemashettar G, Yoon JK, Rasmussen RA, Yang F, Lee SJ, Montefiori DC, Novembre FJ, Villinger F, Amara RR, Kahn M, Hu SL, Li S, Li Z, Frankel FR, Robert-Guroff M, Johnson WE, Lieberman J, Ruprecht RM.
    Vaccine; 2011 Aug 05; 29(34):5611-22. PubMed ID: 21693155
    [Abstract] [Full Text] [Related]

  • 15. The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection.
    Charles TP, Burton SL, Arunachalam PS, Cottrell CA, Sewall LM, Bollimpelli VS, Gangadhara S, Dey AK, Ward AB, Shaw GM, Hunter E, Amara RR, Pulendran B, van Gils MJ, Derdeyn CA.
    PLoS Pathog; 2021 Feb 05; 17(2):e1009257. PubMed ID: 33556148
    [Abstract] [Full Text] [Related]

  • 16. Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.
    Lakhashe SK, Byrareddy SN, Zhou M, Bachler BC, Hemashettar G, Hu SL, Villinger F, Else JG, Stock S, Lee SJ, Vargas-Inchaustegui DA, Cofano EB, Robert-Guroff M, Johnson WE, Polonis VR, Forthal DN, Loret EP, Rasmussen RA, Ruprecht RM.
    Vaccine; 2014 Nov 12; 32(48):6527-36. PubMed ID: 25245933
    [Abstract] [Full Text] [Related]

  • 17. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.
    Quinnan GV, Yu XF, Lewis MG, Zhang PF, Sutter G, Silvera P, Dong M, Choudhary A, Sarkis PT, Bouma P, Zhang Z, Montefiori DC, Vancott TC, Broder CC.
    J Virol; 2005 Mar 12; 79(6):3358-69. PubMed ID: 15731230
    [Abstract] [Full Text] [Related]

  • 18. A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques.
    Zhang P, Narayanan E, Liu Q, Tsybovsky Y, Boswell K, Ding S, Hu Z, Follmann D, Lin Y, Miao H, Schmeisser H, Rogers D, Falcone S, Elbashir SM, Presnyak V, Bahl K, Prabhakaran M, Chen X, Sarfo EK, Ambrozak DR, Gautam R, Martin MA, Swerczek J, Herbert R, Weiss D, Misamore J, Ciaramella G, Himansu S, Stewart-Jones G, McDermott A, Koup RA, Mascola JR, Finzi A, Carfi A, Fauci AS, Lusso P.
    Nat Med; 2021 Dec 12; 27(12):2234-2245. PubMed ID: 34887575
    [Abstract] [Full Text] [Related]

  • 19. Development of a novel rhesus macaque model with an infectious R5 simian-human immunodeficiency virus encoding HIV-1 CRF08_BC env.
    Huang L, Kusagawa S, Zeng H, Yang G, Sun B, Miura T, Yang R.
    J Med Primatol; 2014 Feb 12; 43(1):11-21. PubMed ID: 24020838
    [Abstract] [Full Text] [Related]

  • 20. CD4+ T Cells Are Dispensable for Induction of Broad Heterologous HIV Neutralizing Antibodies in Rhesus Macaques.
    Sarkar S, Spencer DA, Barnette P, Pandey S, Sutton WF, Basu M, Burch RE, Cleveland JD, Rosenberg AF, Rangel-Moreno J, Keefer MC, Hessell AJ, Haigwood NL, Kobie JJ.
    Front Immunol; 2021 Feb 12; 12():757811. PubMed ID: 34745131
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.